Solid Biosciences (SLDB) Total Current Liabilities (2017 - 2024)
Historic Total Current Liabilities for Solid Biosciences (SLDB) over the last 8 years, with Q3 2024 value amounting to $22.9 million.
- Solid Biosciences' Total Current Liabilities rose 4449.92% to $22.9 million in Q3 2024 from the same period last year, while for Sep 2024 it was $22.9 million, marking a year-over-year increase of 4449.92%. This contributed to the annual value of $14.5 million for FY2023, which is 3550.29% down from last year.
- Solid Biosciences' Total Current Liabilities amounted to $22.9 million in Q3 2024, which was up 4449.92% from $14.7 million recorded in Q2 2024.
- In the past 5 years, Solid Biosciences' Total Current Liabilities ranged from a high of $24.5 million in Q4 2020 and a low of $12.9 million during Q1 2020
- In the last 5 years, Solid Biosciences' Total Current Liabilities had a median value of $20.3 million in 2023 and averaged $18.8 million.
- Its Total Current Liabilities has fluctuated over the past 5 years, first surged by 7724.38% in 2021, then plummeted by 3550.29% in 2023.
- Solid Biosciences' Total Current Liabilities (Quarter) stood at $24.5 million in 2020, then decreased by 3.59% to $23.6 million in 2021, then decreased by 4.63% to $22.5 million in 2022, then plummeted by 35.5% to $14.5 million in 2023, then surged by 57.43% to $22.9 million in 2024.
- Its Total Current Liabilities stands at $22.9 million for Q3 2024, versus $14.7 million for Q2 2024 and $14.3 million for Q1 2024.